Company intelligence / Profile preview

Eyeon Therapeutics

Rochester, New York, United States

Ownership: Private
Employees: ~4
Development stage: Other

Overview

The company developed a novel dry eye treatment based on a charged hydrophilic polymer in collaboration with Particle Sciences, receiving a Notice of Allowance on the patent. The platform technology enables drugs to adhere to the eye for extended periods rather than being washed away by tears.

Therapeutic areas: Ophthalmology
Modalities: Small molecule
Industry: Biotech

Partnerships

Particle Sciences (drug delivery CRO partner for formulation development)large pharmaceutical companies as anticipated customers/sublicensees

Beyond the preview

Go deeper on Eyeon Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eyeon Therapeutics.

Explore the full profile